Apr 21, 2024 · Conclusions: In this retrospective analysis of patients failing first line DOAC therapy, rates of 2nd recurrent thrombosis and bleeding did not differ among subsequently chosen anticoagulants.

Nov 29, 2018 · If adequately anticoagulated, the occurrence of thromboembolism (whether primary or recurrent) constitutes treatment failure; this has been reported in approximately 2% of patients in …

Jun 15, 2020 · Another important consideration is the use of add‐on therapy to further mitigate bleeding risk, specifically gastrointestinal bleeding risk in patients on dual therapy.

Oct 19, 2025 · Learn about the side effects of dabigatran, from common to rare, for consumers and healthcare professionals.

Results: In total, 166 patients treated with warfarin, dabigatran, or enoxaparin after antecedent apixaban or rivaroxaban failure (1st recurrent thrombosis) were included (Table 1). 51% and 49% of patients …

Jul 1, 2023 · The purpose of this study was to compare the tolerability and effectiveness of off-label reduced-dose dabigatran (110 mg) with those of the standard dose of 150 mg among high–bleeding …

Mar 3, 2020 · Our case is unique as we discovered undetectable levels of dabigatran providing a mechanism for treatment failure. Additionally, we found therapeutic anticoagulant levels with a …

Apr 17, 2023 · We aimed to describe all cases of dabigatran-reversal failure in the literature to characterize patients at risk of reversal failure in emergency situations after a complete course of …

Oct 17, 2025 · Options for anticoagulation have been expanding steadily over the past few decades, providing a greater number of agents for prevention and management of thromboembolic disease.

Despite exclusion of patients with moderate-to-severe kidney disease from most pivotal DOAC trials, DOACs are increasingly used in this setting. An advantage of DOACs is similar or improved …